RA
BDTX icon

Rise Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Rise Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-646
Closed -$2.45K – 245
2025
Q3 		$2.45K Hold
646
– – ﹤0.01% 1178
2025
Q2 		$1.6K Buy
+646
New +$1.25K ﹤0.01% 1218

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rise Advisors's BDTX Position: Q4 2025 in Review

Rise Advisors sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 646 shares — an estimated $2.45K sold.

Rise Advisors first reported a position in BDTX in Q2 2025 and held it in 2 quarters. The position peaked at $2.45K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

  • Rise Advisors reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 646 Black Diamond Therapeutics shares in Q4 2025, an estimated $2.45K.
  • Rise Advisors first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Black Diamond Therapeutics position peaked at $2.45K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.